Asset / Drug

donanemab

Drug and asset intelligence for donanemab with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Sponsor company

ClinicalJune 17, 2026

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) aims to validate biomarkers and improve clinical trial design for Alzheimer's disease.

Advisory Committee

AdCom outcome will signal FDA tolerance for amyloid-lowering therapies in broader populations.

July 8, 2026 · NDA/BLA

Advisory Committee

AdCom outcome will signal FDA tolerance for amyloid-lowering therapies in broader populations.

July 8, 2026 · NDA/BLA

Topline Data

Monitor the progress of ADNI4 and its findings on biomarkers and cognitive decline predictions.

June 17, 2026 · N/A

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.